Physician profile
Thomas Stark
NPI 1205924008
$2,635.56
in general payments reported to CMS, 2019-2025
14 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $194 · 2021: $353 · 2022: $828 · 2023: $622 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $675.31 | 2020-2025 | |
| Stryker Corporation | $442.73 | 2020-2025 | Scopis Ent |
| Optinose US, INC. | $291.82 | 2019-2023 | |
| Genzyme Corporation | $244.32 | 2020-2023 | |
| Medical Device Business Services, INC. | $233.37 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $221.80 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $145.36 | 2022-2023 | Nucala |
| Acclarent, INC | $131.19 | 2019 | |
| Medtronic, INC. | $122.56 | 2021 | |
| Alk-Abello, INC | $46.55 | 2020-2022 | |
| Kaleo, INC. | $36.14 | 2022 | |
| Integra Lifesciences Corporation | $17.40 | 2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Astrazeneca Pharmaceuticals Lp | $14.01 | 2025 | Tezspire |
| Arbor Pharmaceuticals, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.